Brachytherapy is a type of internal radiation therapy that is used to treat cervical cancer. It involves the application of a radioactive source in close proximity to the tumour. This can be done either by directly inserting the source into (or close to) the tumour using interstitial hollow needles, or by loading the source into an intracavitary applicator that is placed in the vaginal cavity. Standard applicator types may lead to suboptimal radioactive source placement, possibly resulting in underexposure of target volumes and overexposure of organs at risk, especially in advanced cancers. Customised applicators and optimised needle channels based on the patient's MRI/CT data could enhance conformity between target volumes and prescribed isodose. Hence, the goal of this project was to develop and validate a design for a 3D-printed brachytherapy applicator which geometry is based on the patient's vaginal cavity and which features optimised interstitial needle channels based on the patient's anatomy and tumour location. Various analyses have been conducted which have led to the establishment of a list of requirements for the applicator design. Based on this list of requirements, two conceptual designs have been presented: one fully 3D-printed design and one design that is clicked on the Geneva ovoid tubes. Through the creation of prototypes, these conceptual designs have been refined into two final designs which were manufactured in PA12 using selective laser sintering. The dose attenuation properties of PA12 were evaluated and compared to that of water. Furthermore, the potential needle positions within the proximal end of both designs have been analysed. For both designs, a final prototype based on a phantom's vaginal cavity geometry has been created. The usability of these prototypes has been tested by three radiotherapist-oncologists, who also provided feedback on the designs. Upon analysing their feedback and the outcomes of the other evaluations, recommendations for future designs have been formulated. The conducted dosimetry experiment yielded a maximum difference of 0.8% between the average percent dose depth curves of water and PA12, which can be considered a water-equivalent response. This allows PA12 to be used as the material for the applicator. The result of the potential needle position analysis suggest that the first design provides more space for personalised needle channels in the top of the applicator compared to the second design. The three radiotherapist-oncologists validated the usability of both final prototypes. Two designs of a patient-tailored 3D-printed brachytherapy applicator containing optimised interstitial needle channels based on the patient's anatomy and tumour location have been presented, produced and validated. Based on the outcomes of the conducted evaluations, there can be concluded that the first concept shows the most promise to be used as a design for a patient-tailored 3D printed brachytherapy applicator. However, to ensure the proper functioning of the working principles, further development is required. If the recommended improvements are implemented, the design has the potential to be used as applicator in the treatment of cervical cancer.